Skip to content
Menu

Cytokinetics, Incorporated CYTK

Full chart Compare
Set alert

Price alert · CYTK

All alert types
51.46 USD +0.14 (+0.27%)

Regular-session close

51.46 0.00 0.00%

After hours · Nov 19, 4:56 PM ET

50.32 Day range 52.71
51.32 52-week range 87.26
YTD
-19.01%
1 year
-20.57%

5D -1.93 (-3.50%)

545658TueWedThuFriMon53.17
Market cap
7.17B
Revenue (ttm)
113.29M
EPS (ttm)
-6.03
Shares out
139.30M
Forward P/E
-12.16
YTD return
-19.01%
1-year return
-20.57%
50-day average
62.79
200-day average
69.59
Enterprise value
7.45B
Volume
1.74M
Avg volume
2.02M
Open
51.51
Previous close
51.32
Day's range
50.32 – 52.71
52-week range
51.32 – 87.26
Beta
0.47
Analysts
Strong Buy
Price target
109.58 (+112.9%)
Earnings date
Feb 23, 2027

Key statistics

Price / sales
63.28
Revenue growth
2356.50%
Free cash flow
-403.33M
Total cash
1.13B
Total debt
1.43B
Short % of float
19.65%

Fundamental scorecard

6 of 25 checks passed on CYTK’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CYTK Revenue — quarterly 47.56M
CYTK Net income — quarterly -190.07M
CYTK EPS — quarterly -1.37

Earnings

CYTK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 2026-1.41———
Nov 4, 2026Sep 30, 2026-1.43-1.37+0.06+4.20%
Aug 6, 2026Jun 30, 2026-1.63-1.50+0.13+7.98%
May 5, 2026Mar 31, 2026-1.67-1.670.000.00%
Feb 24, 2026Dec 31, 2025-1.48-1.50-0.02-1.35%
Nov 5, 2025Sep 30, 2025-1.59-2.55-0.96-60.38%

Upgrades / downgrades

CYTK analyst upgrades and downgrades
DateFirmActionFromTo
Nov 5, 2026CitigroupmainBuyBuy
Nov 5, 2026Leerink PartnersmainOutperformOutperform
Oct 19, 2026HC Wainwright & Co.reitBuyBuy
Oct 16, 2026William Blairinit—Outperform
Oct 8, 2026RBC CapitalmainOutperformOutperform
Aug 31, 2026HC Wainwright & Co.reitBuyBuy

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CYTK — it syncs with the Stock Master app.

Insider holders

CYTK insider holders
InsiderRelationLatest transactionDateShares held
BHANJI MUNADirectorStock Award(Grant)May 26, 202626,361
BLUM ROBERT IChief Executive OfficerConversion of Exercise of derivative securityNov 15, 2026282,710
CALLOS ANDREWOfficerConversion of Exercise of derivative securityAug 30, 202658,555
HARRINGTON ROBERT ARTHURDirectorStock Award(Grant)Oct 15, 202622,127
HENDERSON JOHN TANNAHILLDirectorStock Award(Grant)Oct 15, 202678,795
HESSEKIEL JEFFREY JOfficerSaleNov 16, 202692,837

Institution ownership

CYTK institution ownership
Holder% heldSharesValueReported
Blackrock Inc.15.10%21,041,1521.08BSep 29, 2026
T. Rowe Price Investment Management, Inc.13.58%18,912,704973.25MSep 29, 2026
Wellington Management Group, LLP7.60%10,590,381544.98MSep 29, 2026
Polar Capital Holdings PLC6.92%9,635,314495.83MSep 29, 2026
State Street Corporation5.13%7,143,229367.59MSep 29, 2026
Vanguard Portfolio Management LLC4.88%6,799,536349.90MSep 29, 2026

Fund ownership

CYTK fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App4.51%6,285,983323.48MJun 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF3.55%4,952,045254.83MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.10%4,314,356222.02MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.51%3,491,654179.68MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund2.40%3,341,262171.94MJul 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.24%3,114,802160.29MJun 29, 2026